Skip Navigation LinksHome > October 1, 2013 - Volume 64 - Issue 2 > Increasing Rate of TAMs and Etravirine Resistance in HIV-1–I...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182a009e4
Epidemiology and Prevention

Increasing Rate of TAMs and Etravirine Resistance in HIV-1–Infected Adults Between 12 and 24 Months of Treatment: The VOLTART Cohort Study in Côte d’Ivoire, West Africa

Messou, Eugène MD, PhD*,†,‡; Chaix, Marie-Laure PhD§; Gabillard, Delphine MSc*,†,‡; Yapo, Vincent PharmD, MSc*,‖; Toni, Thomas-d’Aquin PhD*,‖; Minga, Albert MD, PhD*,†,‡; Kouakou, Martial Guillaume MD*; Ouattara, Eric MD, PhD*,†,‡; Rouzioux, Christine PhD§; Danel, Christine MD, PhD*,†,‡; Eholie, Serge P. MD, MSc*,¶; Anglaret, Xavier MD, PhD*,†,‡

Collapse Box


Background: In sub-Saharan Africa, most HIV-infected patients receive antiretroviral therapy (ART) without virological monitoring. Longitudinal data on secondary resistance are rare.

Methods: We conducted a prospective cohort study of HIV-1–infected adults initiating ART in 3 clinics using computerized monitoring systems. Patients had plasma HIV-1 RNA viral load (VL) tests at months 12 (M12) and 24 (M24) after ART initiation and HIV-1 resistance genotype tests if VL was detectable (≥300 copies/mL).

Results: Overall, 1573 patients initiated ART with stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz. At M12 and M24, 944 and 844 patients, respectively, remained in active follow-up. Among them, 25% (M12) and 27% (M24) had detectable VLs and 12% (M12) and 19% (M24) had virus resistant to at least 1 antiretroviral drug, accounting for 54% (M12) and 75% (M24) of patients with detectable VLs. Among the resistant strains, 95% (M12) and 97% (M24) were resistant to lamivudine/emtricitabine, efavirenz, and/or nevirapine, the frequency of thymidine analog mutations increased from 8.1% (M12) to 14.7% (M24) and etravirine resistance increased from 13.5% (M12) to 24.5% (M24).

Conclusions: Of the patients with detectable VLs at M24, 25% still did not harbor resistant virus. Preventing mutations from emerging with adherence reinforcement in patients with detectable VLs remains important beyond M24. Switching therapy early in patients with resistance to 3 TC/FTC and/or to nonnucleoside reverse transcriptase inhibitors to prevent extended resistance to nucleoside reverse transcriptase inhibitors and etravirine resistance from occurring is also a major challenge.

© 2013 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.